{
 "method": [
  {
   "value": "540",
   "label": "drug CGMP warning letters, 22 January 2021 to 10 November 2026"
  },
  {
   "value": "301",
   "label": "cite at least one of these failures; a letter can sit in several rows"
  },
  {
   "value": "60 of 60",
   "label": "letters read by hand, 15 per row, that match their row"
  },
  {
   "value": "408 of 408",
   "label": "quotes found word for word in the letter text"
  }
 ],
 "hint": "Open a row to see the letters behind its count. The highlight marks FDA's words about the failed record or review.",
 "rows": [
  {
   "id": "211-192",
   "label": "Discrepancies not investigated, or records not reviewed before release",
   "count": 195,
   "records": [
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LGM Pharma Solutions",
     "meta": [
      "2 November 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rohto Pharmaceutical Co.",
     "meta": [
      "14 October 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Silgan Dispensing Systems",
     "meta": [
      "5 October 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Baxter International",
     "meta": [
      "29 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "SnugZ USA",
     "meta": [
      "28 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fresenius Kabi USA",
     "meta": [
      "22 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Bentley Laboratories",
     "meta": [
      "17 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "SCA Pharmaceuticals",
     "meta": [
      "14 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NexCell Scientific",
     "meta": [
      "11 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed, as required by 21 CFR 211.192.",
       "tone": "source",
       "mark": [
        0,
        232
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexcell-scientific-inc-730612-09112026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "kdc/one Chatsworth",
     "meta": [
      "8 September 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jabil",
     "meta": [
      "27 August 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fresenius Medical Care AG & Co. KGaA",
     "meta": [
      "25 August 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Suretec Innovations",
     "meta": [
      "13 August 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/suretec-innovations-llc-730122-08132026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pine Pharmaceuticals",
     "meta": [
      "7 August 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distribut ed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pine-pharmaceuticals-llc-728537-08072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lico Industries, LLC., d.b.a. American Towelette Company",
     "meta": [
      "30 July 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Investigation of any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        39,
        157
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lico-industries-llc-dba-american-towelette-company-729921-07302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Island Kinetics, Inc. d.b.a. CoValence Laboratories",
     "meta": [
      "16 July 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Spa De Soleil",
     "meta": [
      "8 July 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spa-de-soleil-inc-728508-07082026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Medication Systems",
     "meta": [
      "2 July 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-medication-systems-limited-727560-07022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Excelvision - Fareva",
     "meta": [
      "25 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/excelvision-726714-fareva",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Genzyme Ireland",
     "meta": [
      "22 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed, as required by 21 CFR 211.192.",
       "tone": "source",
       "mark": [
        0,
        232
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons Co.",
     "meta": [
      "15 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gopaldas Visram & Co.",
     "meta": [
      "2 June 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.22 and 21 CFR 211.192).",
       "tone": "source",
       "mark": [
        15,
        211
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medline",
     "meta": [
      "28 May 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medline-inc-724347-05282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jubilant HollisterStier General Partnership",
     "meta": [
      "28 May 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jubilant-hollisterstier-general-partnership-723537-05282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmathen International",
     "meta": [
      "27 May 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fagron BV",
     "meta": [
      "12 May 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to thoroughly investigate any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        4,
        204
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-bv-724551-05122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CareFusion 213",
     "meta": [
      "30 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/carefusion-213-llc-722729-04302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Active Cosmetics Manufacturing",
     "meta": [
      "22 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/active-cosmetics-manufacturing-inc-722408-04222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to perform investigations into OOS results obtained during trial injections. (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        26,
        90
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medical Products Laboratories",
     "meta": [
      "9 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medical-products-laboratories-inc-721916-04092026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "ProRx",
     "meta": [
      "7 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lexia",
     "meta": [
      "7 April 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you failed to ensure the following: Investigation of any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        49,
        167
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lexia-llc-722251-04072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "30 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RC Outsourcing",
     "meta": [
      "20 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        210
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rc-outsourcing-llc-722877-03202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "OraLabs",
     "meta": [
      "11 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/oralabs-inc-720690-03112026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tentamus India Private",
     "meta": [
      "3 March 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tentamus-india-private-limited-720463-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "VeganicSKN",
     "meta": [
      "9 February 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/veganicskn-limited-719883-02092026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cohance Lifesciences",
     "meta": [
      "30 January 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cohance-lifesciences-limited-718812-01302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Signature Formulations",
     "meta": [
      "21 January 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Adequate testing of incoming raw materials, including performing identity testing of each shipment of each component (e.g. (b)(4) ) used in the manufac ture of your drug products (21 CFR 211.84(d)(2)) Adequate laboratory controls and specifications (21 CFR 211.160(b)) Adequate design and procedures for production and process controls for drug products and for maintenance and monitoring of your (b)(4) used to manufacture drug products (21 CFR 211.100(a)) Adequate investigations into non-conformances (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        506,
        542
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-718093-01212026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GenoGenix",
     "meta": [
      "20 January 2026",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unex plained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Absolutely Natural",
     "meta": [
      "30 December 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/absolutely-natural-715690-12302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tower Laboratories",
     "meta": [
      "23 December 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tower-laboratories-ltd-717456-12232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Catalent Indiana",
     "meta": [
      "20 November 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/catalent-indiana-llc-718189-11202025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rhyz Analytical Labs",
     "meta": [
      "12 November 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rhyz-analytical-labs-715298-11122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wells Pharma of Houston",
     "meta": [
      "7 November 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wells-pharma-houston-llc-713015-11072025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Siddha Flower Essences, LLC., dba Siddha Remedies",
     "meta": [
      "4 November 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/siddha-flower-essences-llc-dba-siddha-remedies-713217-11042025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Apotex",
     "meta": [
      "31 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apotex-inc-714137-10312025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Owen Biosciences",
     "meta": [
      "30 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        39,
        115
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owen-biosciences-inc-710275-10302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "DermaRite Industries",
     "meta": [
      "27 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermarite-industries-llc-710997-10272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Liebel-Flarsheim Company",
     "meta": [
      "17 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/liebel-flarsheim-company-llc-711508-10172025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "The Tranzonic Companies/Innocore Sales & Marketing",
     "meta": [
      "16 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, the QU failed to ensure: Establishment of an adequate cleaning and maintenance program for your manufacturing equipment and instruments. (21 CFR 211.67(a)) Establishment of adequate batch records to include verification checks, appropriately detailed instructions, and labeling. (21 CFR 211.188) Adequate investigations with sustainable corrective actions including, but not limited to, unknown residues on equipment and out of specification cleaning rinse samples. (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        318,
        477
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tranzonic-companiesinnocore-sales-marketing-inc-712258-10162025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "PQ Pharmacy",
     "meta": [
      "10 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pq-pharmacy-llc-715795-10102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Acme United",
     "meta": [
      "10 October 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.63 and 21 CFR 211.192).",
       "tone": "source",
       "mark": [
        15,
        211
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/acme-united-corporation-712324-10102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Naturich Cosmetique Labs",
     "meta": [
      "25 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/naturich-cosmetique-labs-713565-09252025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Creative Essences",
     "meta": [
      "25 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/creative-essences-inc-710658-09252025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Turbare Manufacturing",
     "meta": [
      "16 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/turbare-manufacturing-713516-09162025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Columbia Cosmetics Manufacturing",
     "meta": [
      "11 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/columbia-cosmetics-manufacturing-inc-710885-09112025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Somerset Therapeutics Private",
     "meta": [
      "4 September 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/somerset-therapeutics-private-limited-711340-09042025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amneal Pharmaceuticals",
     "meta": [
      "27 August 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wisconsin Pharmacal Company",
     "meta": [
      "22 August 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discr epancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals Private",
     "meta": [
      "23 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        205
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Janssen Vaccines Corp., A Johnson & Johnson Company",
     "meta": [
      "18 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/janssen-vaccines-corp-johnson-johnson-company-713194-07182025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Oasis Medical",
     "meta": [
      "15 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/oasis-medical-inc-707198-07152025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "11 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-708270-07112025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Daewoo Pharmaceutical Co.",
     "meta": [
      "2 July 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Investigations (211.192)",
       "tone": "source",
       "mark": [
        0,
        14
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/daewoo-pharmaceutical-co-ltd-706371-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kenil Healthcare Private",
     "meta": [
      "12 June 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate review and approval of production and control records before a batch is released or distributed (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        9,
        104
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kenil-healthcare-private-limited-704786-06122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CTK OTC Laboratories LLC formerly FMK LABS",
     "meta": [
      "19 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ctk-otc-laboratories-llc-formerly-fmk-labs-inc-705479-05192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Evi Labs",
     "meta": [
      "14 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure thorough investigations into unexplained discrepancies or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        16,
        197
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evi-labs-llc-705846-05142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Excelvision Fareva",
     "meta": [
      "7 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/excelvision-fareva-703245-05072025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Staska Pharmaceuticals",
     "meta": [
      "5 May 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/staska-pharmaceuticals-inc-699291-05052025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rechon Life Science AB",
     "meta": [
      "30 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rechon-life-science-ab-701040-04302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "OSRX",
     "meta": [
      "23 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/osrx-inc-701889-04232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tailstorm Health Inc. dba Medivant Health",
     "meta": [
      "8 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailstorm-health-inc-dba-medivant-health-703497-04082025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "PMS4PMS",
     "meta": [
      "7 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        44,
        157
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pms4pms-llc-700180-04072025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Empower Clinic Services, LLC dba Empower Pharma",
     "meta": [
      "2 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharma-700962-04022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NWL Netherlands Services",
     "meta": [
      "1 April 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nwl-netherlands-services-bv-701206-04012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Annovex Pharma",
     "meta": [
      "5 March 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/annovex-pharma-inc-698115-03052025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "ProRx",
     "meta": [
      "4 March 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Chem-Tech",
     "meta": [
      "11 February 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chem-tech-ltd-696920-02112025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "ABR Laboratory",
     "meta": [
      "10 February 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abr-laboratory-llc-696872-02102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Strukmyer LLC dba Strukmyer Medical",
     "meta": [
      "30 January 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strukmyer-llc-dba-strukmyer-medical-692686-01302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Chara Biologics",
     "meta": [
      "17 January 2025",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Review and approval of drug product production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        0,
        227
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chara-biologics-inc-698004-01172025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fagron Compounding Services, LLC dba Fagron Sterile Service",
     "meta": [
      "19 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-compounding-services-llc-dba-fagron-sterile-service-698861-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Viatris",
     "meta": [
      "19 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sombra Cosmetics",
     "meta": [
      "18 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Adequate investigations into customer complaints (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        11,
        50
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sombra-cosmetics-inc-692322-12182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals",
     "meta": [
      "17 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/right-value-drug-stores-llc-dba-carie-boyd-pharmaceuticals-694687-12172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Brands International",
     "meta": [
      "17 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its speci fications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brands-international-corporation-689983-12172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Indoco Remedies",
     "meta": [
      "16 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/indoco-remedies-limited-691594-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Skye Biologics Holdings",
     "meta": [
      "16 December 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192.",
       "tone": "source",
       "mark": [
        0,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/skye-biologics-holdings-llc-654466-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colgate-Palmolive/Tom's of Maine",
     "meta": [
      "5 November 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192 (21 CFR 211.198(a)).",
       "tone": "source",
       "mark": [
        179,
        428
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colgate-palmolivetoms-maine-inc-687043-11052024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Frontier Biologics",
     "meta": [
      "1 November 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Written records are not always made of investigations into unexplained discrepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed , as required by 21 CFR 211.192.",
       "tone": "source",
       "mark": [
        39,
        244
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/frontier-biologics-llc-686059-11012024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pinnacle Transplant Technologies",
     "meta": [
      "1 October 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        200
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-transplant-technologies-llc-646783-10012024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Azurity Pharmaceuticals",
     "meta": [
      "20 September 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm f ailed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        21,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/azurity-pharmaceuticals-inc-656489-09202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zydus Lifesciences",
     "meta": [
      "29 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-685224-08292024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Orean Personal Care",
     "meta": [
      "29 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Adequate investigations into non-conformances are performed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        48,
        98
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orean-personal-care-ltd-682813-08292024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe S.p.A",
     "meta": [
      "15 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accupack Midwest",
     "meta": [
      "15 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Several failures were noted during your firm’s (b)(4) testing on your water samples where your firm resampled and retested the water without an appropriate investigation (see 21 CFR 211.192).",
       "tone": "source",
       "mark": [
        156,
        190
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accupack-midwest-inc-680228-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Greco Gas",
     "meta": [
      "12 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/greco-gas-inc-683090-08122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wittman Pharma",
     "meta": [
      "6 August 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU also failed to ensure: Thorough investigations into deviations and other discrepant results are performed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        40,
        113
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wittman-pharma-inc-683081-08062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CARsgen Therapeutics",
     "meta": [
      "26 July 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch had already been distributed. [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/carsgen-therapeutics-corporation-686504-07262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "EyePoint Pharmaceuticals",
     "meta": [
      "12 July 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eyepoint-pharmaceuticals-inc-679747-07122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Max Chemical",
     "meta": [
      "20 June 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Adequate investigations of in-process testing failures (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        11,
        56
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/max-chemical-inc-682037-06202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sun Pharmaceutical Industries",
     "meta": [
      "18 June 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sun-pharmaceutical-industries-limited-677337-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or n ot the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vegewax Candleworx",
     "meta": [
      "14 June 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm’s quality control unit failed to review and approve all drug product production and control records to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        43,
        225
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vegewax-candleworx-ltd-675099-06142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Westwood Laboratories",
     "meta": [
      "17 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/westwood-laboratories-llc-674728-04172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Natco Pharma",
     "meta": [
      "8 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        194
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natco-pharma-limited-672564-04082024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Stokes Healthcare Inc. dba Epicur Pharma",
     "meta": [
      "2 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm’s quality control unit failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        33,
        229
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stokes-healthcare-inc-dba-epicur-pharma-677624-04022024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Seatex",
     "meta": [
      "1 April 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seatex-llc-672951-04012024-0",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "29 March 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-674736-03292024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "25 March 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-675065-03252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosmetic Specialty Labs",
     "meta": [
      "29 February 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Thorough investigations into out-of-specifications (OOS) results, deviations, and other discrepant results are performed per an adequate written and approved procedure (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        48,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmetic-specialty-labs-inc-671239-02292024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Thai Nakorn Patana Co.",
     "meta": [
      "27 February 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigations and deviations (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        38
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thai-nakorn-patana-co-ltd-672712-02272024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Bell International Laboratories",
     "meta": [
      "15 February 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Adequate investigations into non-conformances (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        48,
        84
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bell-international-laboratories-inc-669736-02152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "QuVa Pharma",
     "meta": [
      "26 January 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quva-pharma-inc-675685-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colgin",
     "meta": [
      "25 January 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications are thoroughly investigated, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        113,
        191
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colgin-inc-670332-01252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Prime Lab",
     "meta": [
      "2 January 2024",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate design and procedures for production and process controls for drug products and for maintenance and monitoring of your water system used to manufacture drug products, including a lack of investigation into out of limit microbiology test results during the installation of your water system (21 CFR 211.100(a) and 211.192)).",
       "tone": "source",
       "mark": [
        196,
        298
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-lab-llc-667057-01022024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "21 November 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-662868-11212023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cipla",
     "meta": [
      "17 November 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cipla-limited-660904-11172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sun Pharmaceutical Industries",
     "meta": [
      "16 October 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sun-pharmaceutical-industries-ltd-636199-10162023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fresenius Kabi",
     "meta": [
      "14 September 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to follow established, approved written procedures and thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        63,
        253
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-ag-657085-09142023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "PureChemPros",
     "meta": [
      "1 September 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Thorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results are performed per an adequate written and approved procedure (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        178
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purechempros-llc-649677-09012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kimera Labs",
     "meta": [
      "1 September 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Written records are not always made of investigations into unexplained dis crepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        39,
        213
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kimera-labs-inc-649343-09012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "US Specialty Formulations",
     "meta": [
      "26 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-specialty-formulations-llc-659142-07262023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Denison Pharmaceuticals",
     "meta": [
      "26 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or fai lure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/denison-pharmaceuticals-llc-654226-07262023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Baxter Healthcare",
     "meta": [
      "25 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-healthcare-corporation-654136-07252023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel Private",
     "meta": [
      "20 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LXR Biotech",
     "meta": [
      "17 July 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigations into non-conformances (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        45
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lxr-biotech-llc-652756-07172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fuller Industries",
     "meta": [
      "28 June 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In addition, some PCMX assay results appeared OOS and were not investigated (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        63,
        75
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fuller-industries-inc-654425-06282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Stratus Biosystems, LLC dba CellGenuity Regenerative Science",
     "meta": [
      "5 June 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        201
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RenatiLabs",
     "meta": [
      "1 June 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your batch records do not include documentation of all investigations made according to 21 CFR 211.192.",
       "tone": "source",
       "mark": [
        55,
        102
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/renatilabs-inc-646353-06012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "New England Life Care, Inc. dba Advanced Compounding Solutions",
     "meta": [
      "16 May 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-england-life-care-inc-dba-advanced-compounding-solutions-659161-05162023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RemedyRepack",
     "meta": [
      "11 May 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedyrepack-inc-649198-05112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Drivergent",
     "meta": [
      "1 May 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigations and deviations (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        38
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/drivergent-inc-647234-05012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmedica USA",
     "meta": [
      "28 April 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Adequate investigations and deviations (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        11,
        40
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmedica-usa-llc-648269-04282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accra-Pac, Inc. dba Voyant Beauty",
     "meta": [
      "20 April 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accra-pac-inc-dba-voyant-beauty-643600-04202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zermat International S.A. de C.V.",
     "meta": [
      "6 April 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zermat-international-sa-de-cv-647232-04062023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Chemical Services Group, Inc./Royal Chemical Company",
     "meta": [
      "5 April 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigation into high colony counts in your (b)(4) system used to generate component (b)(4) water for your drug products. (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chemical-services-group-incroyal-chemical-company-648378-04052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gascó Industrial",
     "meta": [
      "17 February 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications are thoroughly investigated, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        113,
        191
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gasco-industrial-corporation-647393-02172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Midlab Incorporated",
     "meta": [
      "15 February 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/midlab-incorporated-642374-02152023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Frenda",
     "meta": [
      "15 February 2023",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigations and deviations (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        38
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/frenda-corporation-642267-02152023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auto-Chlor System",
     "meta": [
      "20 December 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Thorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        158
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auto-chlor-system-llc-641808-12202022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Premier Nutra Pharma",
     "meta": [
      "9 December 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premier-nutra-pharma-inc-640210-12092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "AG Hair",
     "meta": [
      "28 November 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ag-hair-limited-638646-11282022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Abraxis Bioscience",
     "meta": [
      "31 October 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "During our inspection, our investigators observed specific violations including, but not limited to, the following: Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        27,
        322
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abraxis-bioscience-llc-633713-10312022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center",
     "meta": [
      "21 October 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Nephron SC",
     "meta": [
      "11 October 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nephron-sc-inc-634647-10112022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sovereign Pharmaceuticals",
     "meta": [
      "5 October 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sovereign-pharmaceuticals-llc-634233-10052022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Legacy Pharmaceutical Packaging",
     "meta": [
      "3 October 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/legacy-pharmaceutical-packaging-llc-633735-10032022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sterling Pharmaceutical Services",
     "meta": [
      "27 September 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sterling-pharmaceutical-services-llc-629019-09272022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eco Lips",
     "meta": [
      "20 September 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eco-lips-inc-631629-09202022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "American Cleaning Solutions",
     "meta": [
      "6 September 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Thorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        158
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/american-cleaning-solutions-632881-09062022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Virgin Scent Inc. dba Artnaturals",
     "meta": [
      "1 September 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Gordon Laboratories Inc., Carson, California (FEI 2012546) was issued a Warning Letter on August 17, 2022, for inadequate investigations (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        122,
        136
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/virgin-scent-inc-dba-artnaturals-631780-09012022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Episciences",
     "meta": [
      "25 August 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        199
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/episciences-inc-631902-08252022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BioLab Sciences",
     "meta": [
      "23 August 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        200
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biolab-sciences-inc-621465-08232022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gordon Laboratories",
     "meta": [
      "17 August 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gordon-laboratories-inc-631432-08172022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sagent Pharmaceuticals",
     "meta": [
      "27 July 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sagent-pharmaceuticals-inc-636636-07272022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Bi-Coastal Pharma International",
     "meta": [
      "30 June 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192. (21 CFR 211.198(a)).",
       "tone": "source",
       "mark": [
        179,
        428
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bi-coastal-pharma-international-628196-06302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Monarch PCM",
     "meta": [
      "10 June 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/monarch-pcm-llc-620779-06102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Hybrid Pharma",
     "meta": [
      "7 June 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hybrid-pharma-llc-629021-06072022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aire-Master of America",
     "meta": [
      "23 May 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aire-master-america-inc-622546-05232022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colorful Products",
     "meta": [
      "10 May 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Thorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        164
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colorful-products-corporation-624415-05102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cetylite Industries",
     "meta": [
      "14 April 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cetylite-industries-inc-622823-04142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "The W.S. Badger Company",
     "meta": [
      "12 April 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ws-badger-company-inc-622318-04122022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vi-Jon",
     "meta": [
      "31 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vi-jon-llc-622087-03312022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Verde Cosmetic Labs",
     "meta": [
      "30 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate investigations of out-of-specification (OOS) results and written procedures to conduct thorough investigations (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        9,
        119
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/verde-cosmetic-labs-llc-622534-03302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "NDAL Mfg",
     "meta": [
      "28 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ndal-mfg-inc-621656-03282022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vitae Enim Vitae Scientific",
     "meta": [
      "17 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitae-enim-vitae-scientific-inc-620576-03172022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Generitech",
     "meta": [
      "1 March 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 C FR 211.192).",
       "tone": "source",
       "mark": [
        10,
        224
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/generitech-corporation-618333-03012022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Accu Bio-Chem Laboratories",
     "meta": [
      "24 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accu-bio-chem-laboratories-619450-02242022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yusef Manufacturing Laboratories",
     "meta": [
      "8 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yusef-manufacturing-laboratories-llc-621026-02082022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Smart Surgical, Inc dba Burst Biologics",
     "meta": [
      "2 February 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        202
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/smart-surgical-inc-dba-burst-biologics-614361-02022022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Professional Disposables International",
     "meta": [
      "7 January 2022",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/professional-disposables-international-inc-617201-01072022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Spartan Chemical Company",
     "meta": [
      "15 December 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spartan-chemical-company-inc-614450-12152021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dental Technologies",
     "meta": [
      "30 November 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dental-technologies-inc-612599-11302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Hubei Kangzheng Pharmaceutical Co.",
     "meta": [
      "23 November 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hubei-kangzheng-pharmaceutical-co-ltd-616581-11232021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Surgenex",
     "meta": [
      "15 November 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed. [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        202
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/surgenex-llc-615254-11152021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Infusion Options",
     "meta": [
      "26 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/infusion-options-inc-612459-08262021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Toyobo Co.",
     "meta": [
      "19 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/toyobo-co-ltd-614177-08192021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Utah Cord Bank LLC dba Utah Cell Bank",
     "meta": [
      "10 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].",
       "tone": "source",
       "mark": [
        0,
        202
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Maitland Labs of Central Florida",
     "meta": [
      "6 August 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maitland-labs-central-florida-610102-08062021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanit Technologies, LLC dba Durisan",
     "meta": [
      "27 July 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also failed to open deviations and thoroughly investigate failures in your (b)(4) water system, which produces a component of your drugs, including findings of too numerous to count (TNTC) for microorganisms in water samples. (21 CFR 211.192)",
       "tone": "source",
       "mark": [
        39,
        228
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanit-technologies-llc-dba-durisan-614278-07272021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "American Specialty Pharmacy, Inc. dba ASP Cares",
     "meta": [
      "5 April 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/american-specialty-pharmacy-inc-dba-asp-cares-604003-04052021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Absara Cosmetics S.A.P.I DE C.V.",
     "meta": [
      "18 February 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed, is a violation of CGMP requirements (see 21 CFR 211.192).",
       "tone": "source",
       "mark": [
        0,
        255
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/absara-cosmetics-sapi-de-cv-612455-02182021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Allay Pharmaceuticals",
     "meta": [
      "27 January 2021",
      "21 CFR 211.192"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
       "tone": "source",
       "mark": [
        10,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/allay-pharmaceuticals-llc-609023-01272021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "195 of 540 letters, newest first"
  },
  {
   "id": "data",
   "label": "Data integrity failures",
   "count": 87,
   "records": [
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In your response, you commit to developing an electronic records control procedure, restricting unauthorized modification of spreadsheets used for CGMP data processing, and initiating a retrospective data integrity assessment.",
       "tone": "source",
       "mark": [
        200,
        214
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Conroe Welding Supply",
     "meta": [
      "29 October 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pritam International Private",
     "meta": [
      "27 October 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response is inadequate since you fail to address the severity of the observed data integrity violation for the falsification and alteration of the microbiological test results.",
       "tone": "source",
       "mark": [
        83,
        97
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rohto Pharmaceutical Co.",
     "meta": [
      "14 October 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Notably, we observed critical data integrity breaches in your environmental monitoring (EM), personnel monitoring (PM), and cleaning records.",
       "tone": "source",
       "mark": [
        30,
        53
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Data integrity depends on complete and accurate documentation of test results and conditions.",
       "tone": "source",
       "mark": [
        0,
        14
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Reliance Life Sciences Private",
     "meta": [
      "18 August 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reliance-life-sciences-private-limited-730801-08182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research Pvt.",
     "meta": [
      "12 August 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lico Industries, LLC., d.b.a. American Towelette Company",
     "meta": [
      "30 July 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, your response fails to address significant data integrity lapses documented at your facility which include backdating of quality release labels, entry of temperature data when the thermometer was inoperable, and lack of batch records to document manufacturing activities for drug products.",
       "tone": "source",
       "mark": [
        57,
        78
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lico-industries-llc-dba-american-towelette-company-729921-07302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response is inadequate because it fails to address the severity of the observed data integrity failures.",
       "tone": "source",
       "mark": [
        85,
        99
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BioMylz Pvt.",
     "meta": [
      "13 July 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You did not address your egregious and persistent data integrity issues, nor did you provide any detailed or systemic remediations.",
       "tone": "source",
       "mark": [
        50,
        71
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biomylz-pvt-ltd-729483-07132026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wizcure Pharmaa Private",
     "meta": [
      "24 June 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Our inspectional findings indicate serious recurring data integrity breaches in your laboratory relating to critical microbiological tests and monitoring.",
       "tone": "source",
       "mark": [
        53,
        76
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wizcure-pharmaa-private-limited-726378-06242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Genzyme Ireland",
     "meta": [
      "22 June 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, at the time of the inspection, your firm cancelled numerous deviations without investigating the root cause or assessing product impact. 1 These failures demonstrate a pattern in which your quality unit failed to exercise proper oversight, including oversight of your data integrity practices.",
       "tone": "source",
       "mark": [
        281,
        305
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons Co.",
     "meta": [
      "15 June 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The following day, your firm’s management informed our investigator of critical breaches in data integrity.",
       "tone": "source",
       "mark": [
        92,
        106
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zydus Lifesciences",
     "meta": [
      "2 June 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions.",
       "tone": "source",
       "mark": [
        49,
        63
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-722576-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gopaldas Visram & Co.",
     "meta": [
      "2 June 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https://www.fda.gov/media/119267/download.",
       "tone": "source",
       "mark": [
        28,
        42
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmathen International",
     "meta": [
      "27 May 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, your proposal for a third-party data integrity review using a statistical sampling method is inadequate, as the degree of retrospective review is not sufficient given the significance of the questionable practices documented during the inspection.",
       "tone": "source",
       "mark": [
        46,
        60
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Jaloma S.A. de C.V.",
     "meta": [
      "22 May 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GC America",
     "meta": [
      "14 May 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pro Numb Tattoo Numbing Spray",
     "meta": [
      "14 April 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pro-numb-tattoo-numbing-spray-llc-722589-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You lack an adequate retrospective review to determine the scope and impact of your data integrity issues throughout your facility.",
       "tone": "source",
       "mark": [
        84,
        105
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "ProRx",
     "meta": [
      "7 April 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In fact, the majority of SOPs you provided in your response lack these critical signatories that are essential for Good Documentation Practices (GDP) to ensure accountability, authorization, and data integrity (ALCOA principles: attributable, legible, contemporaneously recorded, original or a true copy, and accurate). 2.",
       "tone": "source",
       "mark": [
        195,
        209
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "30 March 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Effectiveness checks for the CAPAs implemented in your “Data Integrity Risk Assessment” of software applications, conducted by third party consultants in 2024.",
       "tone": "source",
       "mark": [
        56,
        70
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Microbiological Testing & Consulting",
     "meta": [
      "16 March 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/microbiological-testing-consulting-llc-720374-03162026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Patcos Cosmetics Pvt.",
     "meta": [
      "12 March 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/patcos-cosmetics-pvt-ltd-718220-03122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Tentamus India Private",
     "meta": [
      "3 March 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also do not propose any global action s to address the data integrity culture at your firm, identify the root cause of continued documentation and data integrity deficiencies, implement adequate controls, or create an environment that prioritizes the handling of data with integrity.",
       "tone": "source",
       "mark": [
        59,
        73
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tentamus-india-private-limited-720463-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fareva Morton Grove",
     "meta": [
      "3 March 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response also lacks steps to systemically address your inadequate oversight of data integrity, including but not limited to improving your quality-assurance function.",
       "tone": "source",
       "mark": [
        84,
        98
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-morton-grove-719408-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "A. Nelson & Co.",
     "meta": [
      "12 February 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "These deficiencies raise significant data integrity concerns as critical quality records were improperly discarded.",
       "tone": "source",
       "mark": [
        37,
        60
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nelson-co-ltd-720283-02122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fulijaya Manufacturing SDN. BHD.",
     "meta": [
      "14 January 2026"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your elimination of internal HPLC testing does not address your fundamental breaches of data integrity.",
       "tone": "source",
       "mark": [
        88,
        102
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "DermaRite Industries",
     "meta": [
      "27 October 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermarite-industries-llc-710997-10272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Kangping Medical Science and Technology Co.",
     "meta": [
      "9 October 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Guangxi Yulin Pharmaceutical Group Co.",
     "meta": [
      "30 September 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangxi-yulin-pharmaceutical-group-co-ltd-710422-09302025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Persōn & Covey",
     "meta": [
      "23 September 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/person-covey-inc-711191-09232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shiva Analyticals Private",
     "meta": [
      "23 July 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Data integrity is critical throughout the CGMP data lifecycle, including in the creation, modification, processing, maintenance, archival, retrieval, and transmission of data.",
       "tone": "source",
       "mark": [
        0,
        14
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shiva-analyticals-private-limited-707857-07232025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Moreover, your response lacks an assessment of potential data integrity concerns associated with one-person verification.",
       "tone": "source",
       "mark": [
        57,
        80
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kenil Healthcare Private",
     "meta": [
      "12 June 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kenil-healthcare-private-limited-704786-06122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zhejiang Huahai Pharmaceutical Co.",
     "meta": [
      "6 June 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Data Integrity During the inspection, our investigator observed a laboratory employee who appeared to be approving environmental monitoring records non-contemporaneously (or “backdating”).",
       "tone": "source",
       "mark": [
        0,
        14
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-huahai-pharmaceutical-co-ltd-707145-06062025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosco International",
     "meta": [
      "14 April 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The assessment should also include, but not be limited to: o A determination of whether procedures used by your firm are robust and appropriate. o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision. o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. o An assessment of the extent of data integrity deficiencies at your facility.",
       "tone": "source",
       "mark": [
        540,
        567
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosco-international-inc-701209-04142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou Sion Commodity Co.",
     "meta": [
      "12 March 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response is inadequate, as you fail to fully consider comprehensive data integrity (DI) remediation to address the gaps and uncertainties caused by a significant adverse pattern of data that was discarded, lost, or not recorded contemporaneously.",
       "tone": "source",
       "mark": [
        73,
        87
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-sion-commodity-co-ltd-699183-03122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response is inadequate as it does not adequately evaluate the full scope of data integrity (DI) deficiencies throughout your drug product manufacturing operations.",
       "tone": "source",
       "mark": [
        81,
        95
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Granules India",
     "meta": [
      "26 February 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You identified several root causes for these issues, including insufficient clarity in good documentation practices and data integrity protocols, inadequate SOP provisions requiring the attachment of defective or illegible printouts with appropriate annotations, employee misinterpretation of existing procedures, and inadequate controls over raw data sheets for primary packaging materials.",
       "tone": "source",
       "mark": [
        120,
        134
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/granules-india-limited-697115-02262025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aspen Pharmacare Holdings",
     "meta": [
      "24 February 2025"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release.",
       "tone": "source",
       "mark": [
        85,
        99
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-pharmacare-holdings-limited-701671-02242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Viatris",
     "meta": [
      "19 December 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "It fails to provide sufficient details regarding the extent of the identified data integrity issues, and the thoroughness of your proposed corrective and preventive actions (CAPAs) is unclear.",
       "tone": "source",
       "mark": [
        78,
        99
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences, Private",
     "meta": [
      "6 November 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You do not provide sufficient details describing how data integrity deficiencies will be detected and documented by your third-party consultant.",
       "tone": "source",
       "mark": [
        53,
        80
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "MMC Healthcare",
     "meta": [
      "24 September 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmc-healthcare-ltd-684644-09242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe S.p.A",
     "meta": [
      "15 August 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "These systemic data integrity issues involved numerous production and quality assurance staff and were occurring at your facility for multiple months.",
       "tone": "source",
       "mark": [
        15,
        36
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Greco Gas",
     "meta": [
      "12 August 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/greco-gas-inc-683090-08122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jiangsu Hengrui Pharmaceuticals Co.",
     "meta": [
      "11 July 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• An assessment of the extent of data integrity deficiencies at your facility.",
       "tone": "source",
       "mark": [
        33,
        60
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangsu-hengrui-pharmaceuticals-co-ltd-679790-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Brassica Pharma Pvt.",
     "meta": [
      "11 July 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Microbiology Laboratory Data Integrity Your firm failed to test every batch for sterility as required by your procedures.",
       "tone": "source",
       "mark": [
        24,
        38
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brassica-pharma-pvt-ltd-679005-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response, regarding your firm’s failure to document laboratory data at the time of performance, did not include documentation to show employee training on COP-CAPS-4000014, Data Integrity Requirements, and training and implementation of the referenced SOP-CAPS 4000390, Controlled Data Sheets, at CAPS remaining 503B sites.",
       "tone": "source",
       "mark": [
        178,
        192
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Optikem International",
     "meta": [
      "20 June 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Furthermore, persistently deficient environmental controls (e.g., poor design of facility and processing lines, lack of data integrity, and inadequate and insufficient EM) provide a fundamental lack of meaningful retrospective data to support (b)(4) sterility assurance.",
       "tone": "source",
       "mark": [
        120,
        134
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optikem-international-inc-680264-06202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You indicate you have a procedure to address data integrity concerns.",
       "tone": "source",
       "mark": [
        45,
        68
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Landy International",
     "meta": [
      "12 June 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/landy-international-679066-06122024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico SRL",
     "meta": [
      "30 April 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Westwood Laboratories",
     "meta": [
      "17 April 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Moreover, your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        61,
        91
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/westwood-laboratories-llc-674728-04172024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kilitch Healthcare India",
     "meta": [
      "28 March 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "This response is not adequate as it does not address the data integrity issues that were identified by FDA.",
       "tone": "source",
       "mark": [
        57,
        78
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kilitch-healthcare-india-limited-672956-03282024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amman Pharmaceutical Industries",
     "meta": [
      "14 February 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Laboratory data indicating the absence of microbial recovery cannot be considered valid in light of the significant data integrity breach es that call into question the general reliability of your firm’s test results.",
       "tone": "source",
       "mark": [
        116,
        130
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amman-pharmaceutical-industries-668867-02142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises Public Company",
     "meta": [
      "26 January 2024"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "21 November 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Production managers including, but not limited to, front line supervisors failed to ensure reliable data, leading to significant data integrity deficiencies in your production records.",
       "tone": "source",
       "mark": [
        129,
        156
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-662868-11212023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cipla",
     "meta": [
      "17 November 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "In response to this letter, provide the following: An assessment of the extent of data integrity deficiencies at your facility.",
       "tone": "source",
       "mark": [
        82,
        109
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cipla-limited-660904-11172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Global Pharma Healthcare Private",
     "meta": [
      "20 October 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• You do not assess all records potentially affected by lapses in data integrity.",
       "tone": "source",
       "mark": [
        66,
        80
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/global-pharma-healthcare-private-limited-657325-10202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Safecor Health",
     "meta": [
      "5 September 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response is inadequate because while you indicate that training was provided to employees on good document ation practices, you did not conduct a comprehensive review to determine the extent of data integrity issues at your facility.",
       "tone": "source",
       "mark": [
        199,
        220
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safecor-health-llc-657886-09052023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lex",
     "meta": [
      "17 August 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your response does not provide adequate details of required improvements and expertise (e.g., management oversight, competencies) to assure data integrity.",
       "tone": "source",
       "mark": [
        140,
        154
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lex-inc-656056-08172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosmobeauti Laboratories & Manufacturing",
     "meta": [
      "11 August 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmobeauti-laboratories-manufacturing-inc-657682-08112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Senior facility managers failed to exercise their authority and responsibility to ensure rel iable data, leading to severe data integrity deficiencies in your production and laboratory departments.",
       "tone": "source",
       "mark": [
        123,
        150
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medgel Private",
     "meta": [
      "20 July 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate data integrity controls (e.g., your QU failed to adequately restrict access to analytical instruments; you used shared usernames and passwords).",
       "tone": "source",
       "mark": [
        12,
        35
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medgel-private-limited-654085-07202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zermat International S.A. de C.V.",
     "meta": [
      "6 April 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zermat-international-sa-de-cv-647232-04062023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sure-Biochem Laboratories",
     "meta": [
      "24 March 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sure-biochem-laboratories-llc-646619-03242023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Omega Packaging",
     "meta": [
      "20 March 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/omega-packaging-corp-649122-03202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dunagin Pharmaceuticals Inc. dba Massco Dental",
     "meta": [
      "22 February 2023"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dunagin-pharmaceuticals-inc-dba-massco-dental-644335-02222023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kari Gran",
     "meta": [
      "30 November 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kari-gran-inc-640035-11302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Beijing Xinggu Lvsan Technology Co., Ltd. Formerly known as Beijing Lvsan Technology Co.",
     "meta": [
      "5 October 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beijing-xinggu-lvsan-technology-co-ltd-formerly-known-beijing-lvsan-technology-co-ltd-633904",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Advanced Cosmetic Research Laboratories",
     "meta": [
      "26 September 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "An assessment of the extent of data integrity deficiencies at your facility.",
       "tone": "source",
       "mark": [
        31,
        58
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/advanced-cosmetic-research-laboratories-inc-635176-09262022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh",
     "meta": [
      "9 September 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/system-kosmetik-produktionsgesellschaft-fur-kosmetische-gmbh-632727-09092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Monarch PCM",
     "meta": [
      "10 June 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/monarch-pcm-llc-620779-06102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Colorful Products",
     "meta": [
      "10 May 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colorful-products-corporation-624415-05102022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Vi-Jon",
     "meta": [
      "31 March 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vi-jon-llc-622087-03312022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sanitor",
     "meta": [
      "29 November 2021"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitor-corporation-616232-11292021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your investigation lacked a comprehensive assessment into the extent of the falsification of autoclave records and other breaches of data integrity occurring in the laboratory.",
       "tone": "source",
       "mark": [
        133,
        147
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Toyobo Co.",
     "meta": [
      "19 August 2021"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your investigation into data integrity breaches, reported to the agency in a (b)(4) , was insufficient to determine the scope of the problems at your facility.",
       "tone": "source",
       "mark": [
        24,
        47
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/toyobo-co-ltd-614177-08192021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Adamson Analytical Laboratories",
     "meta": [
      "17 August 2021"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test.",
       "tone": "source",
       "mark": [
        51,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/adamson-analytical-laboratories-inc-614644-08172021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
       "tone": "source",
       "mark": [
        41,
        71
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "87 of 540 letters, newest first"
  },
  {
   "id": "211-188",
   "label": "Batch production records incomplete or missing",
   "count": 77,
   "records": [
    {
     "title": "SnugZ USA",
     "meta": [
      "28 September 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate documentation of each significant step in batch production records (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        51,
        75
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Babikian Healthcare Products CJSC",
     "meta": [
      "21 September 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Maintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        89,
        102
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "TCI Co., Ltd BioCosme PABP BRANCH",
     "meta": [
      "2 September 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Additionally, the following are examples of poor QU oversight: The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing. 21 CFR 211.188(b) There is no written testing program designed to assess the stability characteristics of drug products. 21 CFR 211.166(a) An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.",
       "tone": "source",
       "mark": [
        67,
        467
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Jabil",
     "meta": [
      "27 August 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Notably, critical interventions, including but not limited to removing vials from the filling zone and removing fallen vials from (b)(4) , were not documented. (21 CFR 211.188)",
       "tone": "source",
       "mark": [
        139,
        158
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lico Industries, LLC., d.b.a. American Towelette Company",
     "meta": [
      "30 July 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        0,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lico-industries-llc-dba-american-towelette-company-729921-07302026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Woodbine Products Company",
     "meta": [
      "27 July 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/woodbine-products-company-inc-729345-07272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "IDO Pharm Co.",
     "meta": [
      "4 May 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ido-pharm-co-ltd-723449-05042026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pro Numb Tattoo Numbing Spray",
     "meta": [
      "14 April 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Establishment of adequate batch production and control records, with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        65,
        206
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pro-numb-tattoo-numbing-spray-llc-722589-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Lexia",
     "meta": [
      "7 April 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lexia-llc-722251-04072026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RC Outsourcing",
     "meta": [
      "20 March 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rc-outsourcing-llc-722877-03202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou H&R Plastic Daily Chemical Co.",
     "meta": [
      "18 March 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Consistent and complete batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        37
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-hr-plastic-daily-chemical-co-ltd-722736-03182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Patcos Cosmetics Pvt.",
     "meta": [
      "12 March 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure that batch production and control records are complete (2 1 CFR 211.188) Ensure adequate specifications, sampling plans, and test methods for components and drug products to assure they conform to appropriate standards of identity, strength, quality and purity (21 CFR 211.160(b)).",
       "tone": "source",
       "mark": [
        12,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/patcos-cosmetics-pvt-ltd-718220-03122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "AQ USA Inc., d.b.a Ross Healthcare",
     "meta": [
      "12 February 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aq-usa-inc-dba-ross-healthcare-inc-719517-02122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GenoGenix",
     "meta": [
      "20 January 2026",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LiquidCapsule Manufacturing",
     "meta": [
      "19 December 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/liquidcapsule-manufacturing-llc-717069-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Apothecary Pharma",
     "meta": [
      "1 December 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "CDL Services, Inc. DBA Technichem",
     "meta": [
      "24 November 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdl-services-inc-dba-technichem-713877-11242025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Miers Laboratories",
     "meta": [
      "3 November 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your QU failed to ensure the following: Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        52,
        201
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/miers-laboratories-ltd-715378-11032025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Uriel Pharmacy",
     "meta": [
      "21 October 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your batch records do not include all critical steps and verifications (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        5,
        70
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/uriel-pharmacy-inc-709977-10212025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "The Tranzonic Companies/Innocore Sales & Marketing",
     "meta": [
      "16 October 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, the QU failed to ensure: Establishment of an adequate cleaning and maintenance program for your manufacturing equipment and instruments. (21 CFR 211.67(a)) Establishment of adequate batch records to include verification checks, appropriately detailed instructions, and labeling. (21 CFR 211.188)",
       "tone": "source",
       "mark": [
        195,
        290
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tranzonic-companiesinnocore-sales-marketing-inc-712258-10162025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Foshan Yiying Hygiene Products Co.",
     "meta": [
      "10 October 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/foshan-yiying-hygiene-products-co-ltd-715548-10102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Everlaan Organics, Inc. dba Maple Organics",
     "meta": [
      "11 August 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/everlaan-organics-inc-dba-maple-organics-707956-08112025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Health and Natural Beauty USA",
     "meta": [
      "28 July 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        26,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/health-and-natural-beauty-usa-corp-700187-07282025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Gussyup LLC dba Private Label Grooming",
     "meta": [
      "9 July 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        9,
        225
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gussyup-llc-dba-private-label-grooming-709488-07092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medical Chemical",
     "meta": [
      "9 July 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure the following: Establishment and review of adequate batch production and control records for each batch of drug product which include complete information regarding each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        90,
        289
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medical-chemical-corporation-706007-07092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Healwell Homeo Private",
     "meta": [
      "12 June 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        12,
        161
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healwell-homeo-private-limited-706206-06122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kenil Healthcare Private",
     "meta": [
      "12 June 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        9,
        225
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kenil-healthcare-private-limited-704786-06122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amish Origins Management",
     "meta": [
      "29 May 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amish-origins-management-llc-704166-05292025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Zhejiang Easyclean Daily Chemical Co.",
     "meta": [
      "14 May 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-easyclean-daily-chemical-co-ltd-702295-05142025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rite-Kem Incorporated",
     "meta": [
      "28 January 2025",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        12,
        161
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rite-kem-incorporated-697272-01282025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Skye Biologics Holdings",
     "meta": [
      "16 December 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b).",
       "tone": "source",
       "mark": [
        19,
        200
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/skye-biologics-holdings-llc-654466-12162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        0,
        207
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dr. Brite",
     "meta": [
      "21 November 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Batch production records were maintained (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        2,
        42
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-brite-llc-684466-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurosirel S.P.A",
     "meta": [
      "20 November 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Complete batch and control records for each batch of drug product (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        9,
        65
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-11202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences, Private",
     "meta": [
      "6 November 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        22,
        162
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Hangzhou Glamcos Biotech Co.",
     "meta": [
      "7 October 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hangzhou-glamcos-biotech-co-ltd-692583-10072024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aromas Para El Alma",
     "meta": [
      "10 September 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aromas-para-el-alma-sa-672728-09102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Clean Solutions",
     "meta": [
      "6 September 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        14,
        163
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clean-solutions-llc-686995-09062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Orean Personal Care",
     "meta": [
      "29 August 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate systems for document control and retention are established and followed (e.g., missing, or incomplete batch records, missing testing records and out-of-specification (OOS) investigations) (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        111,
        196
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orean-personal-care-ltd-682813-08292024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "AnuMed International",
     "meta": [
      "20 August 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Batch production and control records include documentation of the accomplishment of each significant step in the manufacture and processing for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        2,
        172
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anumed-international-llc-674310-08202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kaylaan",
     "meta": [
      "19 August 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Preparation of batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        15,
        222
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kaylaan-llc-681977-08192024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Regenerative Processing Plant",
     "meta": [
      "16 August 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced, including specific identification of each batch of component or in-process material used [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        28,
        258
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/regenerative-processing-plant-llc-672154-08162024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aerosol and Liquid Packaging",
     "meta": [
      "24 July 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Consistent and complete batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        37
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aerosol-and-liquid-packaging-inc-676746-07242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Safari Stem Cell",
     "meta": [
      "5 April 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        19,
        316
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safari-stem-cell-llc-661023-04052024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Bodywell Natural Skin Care",
     "meta": [
      "27 March 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bodywell-natural-skin-care-inc-677099-03272024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Higley Industries",
     "meta": [
      "22 February 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        9,
        216
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/higley-industries-inc-669170-02222024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Bell International Laboratories",
     "meta": [
      "15 February 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate system for document control and retention (e.g., missing, or incomplete batch records, missing testing records and out-of-specification (OOS) investigations) (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        81,
        166
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bell-international-laboratories-inc-669736-02152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Les Importations Herbasanté",
     "meta": [
      "31 January 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Batch production and control records include documentation of the accomplishment of each significant step in the manufacture, and processing, of the batch, for each batch of drug product (21 CFR 211 .188(b)).",
       "tone": "source",
       "mark": [
        0,
        186
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/les-importations-herbasante-inc-668412-01312024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "S & J International Enterprises Public Company",
     "meta": [
      "26 January 2024",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/s-j-international-enterprises-public-company-limited-668482-01262024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "PureChemPros",
     "meta": [
      "1 September 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Preparation of adequate batch control and production records for your drug products (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        83
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purechempros-llc-649677-09012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosmobeauti Laboratories & Manufacturing",
     "meta": [
      "11 August 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100(a) and 21 CFR 211.188).",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmobeauti-laboratories-manufacturing-inc-657682-08112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LXR Biotech",
     "meta": [
      "17 July 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Consistent and complete batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        37
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lxr-biotech-llc-652756-07172023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Mr. Lulu",
     "meta": [
      "1 June 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100 (a) and 21 CFR 211.188) Process Validation You failed to validate your manufacturing processes for your OTC drug prod ucts and failed to provide assurance that you are capable of consistently manufacturing a drug product with defined quality attributes.",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mr-lulu-llc-650772-06012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "RenatiLabs",
     "meta": [
      "1 June 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records for each batch of drug product produced that include documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        19,
        231
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/renatilabs-inc-646353-06012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Drivergent",
     "meta": [
      "1 May 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate maintenance of batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        37
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/drivergent-inc-647234-05012023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pharmedica USA",
     "meta": [
      "28 April 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Consistent and complete batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        26,
        39
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmedica-usa-llc-648269-04282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Omega Packaging",
     "meta": [
      "20 March 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Adequate batch control and production records for your hand sanitizer drug products (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        9,
        83
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/omega-packaging-corp-649122-03202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Cosmetic Science Laboratories",
     "meta": [
      "10 March 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100 (a) and 21 CFR211.188).",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmetic-science-laboratories-llc-645558-03102023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Frenda",
     "meta": [
      "15 February 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Consistent and complete batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        24,
        37
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/frenda-corporation-642267-02152023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Atlantic Management Resources LTD dba. Claire Ellen Products",
     "meta": [
      "20 January 2023",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/atlantic-management-resources-ltd-dba-claire-ellen-products-642082-01202023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auto-Chlor System",
     "meta": [
      "20 December 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "To prepare adequate batch control and production records for your hand sanitizer drug products (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        20,
        94
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auto-chlor-system-llc-641808-12202022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ultra Chem Labs",
     "meta": [
      "20 December 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "To prepare adequate batch control and production records for your hand sanitizer drug products (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        20,
        94
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-chem-labs-corporation-641742-12202022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Premier Nutra Pharma",
     "meta": [
      "9 December 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premier-nutra-pharma-inc-640210-12092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kari Gran",
     "meta": [
      "30 November 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100 (a) and 21 CFR 211.188).",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kari-gran-inc-640035-11302022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Glenmark Pharmaceuticals",
     "meta": [
      "22 November 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product pr oduced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        169
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glenmark-pharmaceuticals-limited-637314-11222022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Invitrx Therapeutics",
     "meta": [
      "9 November 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        19,
        316
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invitrx-therapeutics-inc-630712-11092022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eksa Mills S.A. de C.V.",
     "meta": [
      "5 October 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• Adequate maintenance of batch records (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        26,
        39
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eksa-mills-sa-de-cv-634706-10052022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Virgin Scent Inc. dba Artnaturals",
     "meta": [
      "1 September 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Since 2022, the FDA has taken the following actions in response to FD&C Act violations or deficiencies found at your contract manufacturers. (b)(4) was issued a Warning Letter dated (b)(4) , for having an inadequate quality control unit (21 CFR 211.22(a) and 211.22(d)), failing to examine incoming components (21 CFR 211.84(a)), failing to perform release testing prior to product release (21 CFR 211.165(a)), and failing to record manufacturing information in a batch record (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        464,
        476
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/virgin-scent-inc-dba-artnaturals-631780-09012022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Re-Gen Active Lab",
     "meta": [
      "27 May 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records for each batch of drug product produced that include complete inform ation relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        19,
        317
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/re-gen-active-lab-inc-620763-05272022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fresh Farms",
     "meta": [
      "19 April 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
       "tone": "source",
       "mark": [
        28,
        168
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresh-farms-llc-623723-04192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Premier Trends",
     "meta": [
      "14 March 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.186(a) and 211.188).",
       "tone": "source",
       "mark": [
        33,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premier-trends-llc-621313-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dr Retter Ec Wladyslaw Retter",
     "meta": [
      "14 March 2022",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-retter-ec-wladyslaw-retter-619881-03142022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine",
     "meta": [
      "10 November 2021",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records for each batch of drug produ ct that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Utah Cord Bank LLC dba Utah Cell Bank",
     "meta": [
      "10 August 2021",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)",
       "tone": "source",
       "mark": [
        19,
        316
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Honest Globe",
     "meta": [
      "15 March 2021",
      "21 CFR 211.188"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).",
       "tone": "source",
       "mark": [
        28,
        235
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/honest-globe-inc-597177-03152021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "77 of 540 letters, newest first"
  },
  {
   "id": "211-194",
   "label": "Laboratory records incomplete",
   "count": 49,
   "records": [
    {
     "title": "Natural Essentials",
     "meta": [
      "10 November 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Pritam International Private",
     "meta": [
      "27 October 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Rohto Pharmaceutical Co.",
     "meta": [
      "14 October 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a)",
       "tone": "source",
       "mark": [
        348,
        365
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eurofins SF Analytical Laboratories",
     "meta": [
      "6 October 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Hanlim Pharm Co.",
     "meta": [
      "2 October 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Contemporaneous documentation of EM and personnel monitoring sampling data in laboratory records (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        70,
        96
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Reliance Life Sciences Private",
     "meta": [
      "18 August 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reliance-life-sciences-private-limited-730801-08182026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Auriga Research Pvt.",
     "meta": [
      "12 August 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Dabur India",
     "meta": [
      "24 July 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dabur-india-limited-728828-07242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Wizcure Pharmaa Private",
     "meta": [
      "24 June 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wizcure-pharmaa-private-limited-726378-06242026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Genzyme Ireland",
     "meta": [
      "22 June 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to ensure that laboratory records include complete data derived from all tests necessary to assure compliance with established specifications and standards, as required by 21 CFR 211.194(a).",
       "tone": "source",
       "mark": [
        23,
        197
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Huons Co.",
     "meta": [
      "15 June 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/huons-co-ltd-724650-06152026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Laboratorios Jaloma S.A. de C.V.",
     "meta": [
      "22 May 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Respilon Production S.R.O.",
     "meta": [
      "20 April 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/respilon-production-sro-719705-04202026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Patcos Cosmetics Pvt.",
     "meta": [
      "12 March 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Specifically, your QU failed to: Ensure adequate control over laboratory data including deliberate alteration of original data to conceal out-of-specification results (21 CFR 211.194).",
       "tone": "source",
       "mark": [
        62,
        166
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/patcos-cosmetics-pvt-ltd-718220-03122026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fareva Morton Grove",
     "meta": [
      "3 March 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-morton-grove-719408-03032026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fulijaya Manufacturing SDN. BHD.",
     "meta": [
      "14 January 2026",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unipack",
     "meta": [
      "19 December 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unipack-llc-716621-12192025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Seaway Pharma",
     "meta": [
      "1 December 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "• laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a))",
       "tone": "source",
       "mark": [
        2,
        143
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seaway-pharma-inc-717355-12012025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "DermaRite Industries",
     "meta": [
      "27 October 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure the following: Performance of annual product reviews (21 CFR 211.180(e)) Performance of adequate testing of component (e.g., water) (211.22(d)) COA included all data derived from actual testing performed (211.194(a))",
       "tone": "source",
       "mark": [
        182,
        241
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermarite-industries-llc-710997-10272025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Health and Natural Beauty USA",
     "meta": [
      "28 July 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Laboratory records that included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194).",
       "tone": "source",
       "mark": [
        0,
        146
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/health-and-natural-beauty-usa-corp-700187-07282025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Medical Chemical",
     "meta": [
      "9 July 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment and review of adequate laboratory records which include all data obtained during testing (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        37,
        102
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medical-chemical-corporation-706007-07092025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Exela Pharma Sciences",
     "meta": [
      "2 July 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Shantou S.E.Z. Baojie Industry Co.",
     "meta": [
      "15 April 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Verification of testing methods to ensure accurate, precise, and reliable results (21 CFR 211.194(a)",
       "tone": "source",
       "mark": [
        0,
        81
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shantou-sez-baojie-industry-co-ltd-703439-04152025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Taizhou Jingshang Cosmetics Technology Co.",
     "meta": [
      "2 April 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Yangzhou Sion Commodity Co.",
     "meta": [
      "12 March 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-sion-commodity-co-ltd-699183-03122025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "Read the letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Unexo Lifesciences, Private",
     "meta": [
      "6 November 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21CFR211.194(a)).",
       "tone": "source",
       "mark": [
        26,
        185
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Avaria Health & Beauty",
     "meta": [
      "3 September 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to ensure: Verification of testing methods to ensure accurate, precise, and reliable results (21 CFR 211.194(a)",
       "tone": "source",
       "mark": [
        39,
        120
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/avaria-health-beauty-corp-685248-09032024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intercos Europe S.p.A",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intercos-europe-spa-682273-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Eugia Pharma Specialities",
     "meta": [
      "15 August 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-681905-08152024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Aerosol and Liquid Packaging",
     "meta": [
      "24 July 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, you failed to ensure: Laboratory records include complete data derived from all tests to assure compliance (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        35,
        119
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aerosol-and-liquid-packaging-inc-676746-07242024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Brassica Pharma Pvt.",
     "meta": [
      "11 July 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brassica-pharma-pvt-ltd-679005-07112024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Optikem International",
     "meta": [
      "20 June 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, our inspection found missing original data in your laboratory and production operations (21 CFR 211.194 & 211.100).",
       "tone": "source",
       "mark": [
        42,
        100
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optikem-international-inc-680264-06202024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "GFA Production Xiamen Co.",
     "meta": [
      "13 June 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gfa-production-xiamen-co-ltd-678364-06132024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Grupo Quimico SRL",
     "meta": [
      "30 April 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "FirstCham Co.",
     "meta": [
      "3 April 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/firstcham-co-ltd-672903-04032024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Kilitch Healthcare India",
     "meta": [
      "28 March 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all test s necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        174
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kilitch-healthcare-india-limited-672956-03282024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Thai Nakorn Patana Co.",
     "meta": [
      "27 February 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Complete data derived from standard preparation, sample preparation, and assay testing of your drug products was properly documented and retained (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        9,
        145
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thai-nakorn-patana-co-ltd-672712-02272024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Amman Pharmaceutical Industries",
     "meta": [
      "14 February 2024",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amman-pharmaceutical-industries-668867-02142024",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Similasan",
     "meta": [
      "11 September 2023",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. (21 CFR 211.194(a))",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/similasan-ag-658878-09112023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Intas Pharmaceuticals",
     "meta": [
      "28 July 2023",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Fuller Industries",
     "meta": [
      "28 June 2023",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate identification of samples listed on test records. (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        65,
        77
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fuller-industries-inc-654425-06282023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Sure-Biochem Laboratories",
     "meta": [
      "24 March 2023",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sure-biochem-laboratories-llc-646619-03242023",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center",
     "meta": [
      "21 October 2022",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Laboratory records are deficient in that they do not include the initials and signatu re of the second person reviewing the record for accuracy (21 CFR 211.194 (a)",
       "tone": "source",
       "mark": [
        0,
        143
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
       "tone": "source",
       "mark": [
        32,
        173
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "Read the letter"
    },
    {
     "title": "Utah Cord Bank LLC dba Utah Cell Bank",
     "meta": [
      "10 August 2021",
      "21 CFR 211.194"
     ],
     "tags": [
      {
       "label": "Warning letter",
       "tone": "warn"
      }
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)",
       "tone": "source",
       "mark": [
        22,
        411
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021",
     "urlLabel": "Read the letter"
    }
   ],
   "note": "49 of 540 letters, newest first"
  }
 ],
 "download": "Every card is in the {json}, and the counts by year are in the CSV below."
}
